Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Construction in Progress (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Construction in Progress for 9 consecutive years, with $127.2 million as the latest value for Q4 2025.

  • Quarterly Construction in Progress fell 80.56% to $127.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $127.2 million through Dec 2025, down 80.56% year-over-year, with the annual reading at $127.2 million for FY2025, 80.56% down from the prior year.
  • Construction in Progress for Q4 2025 was $127.2 million at BeOne Medicines, down from $129.1 million in the prior quarter.
  • The five-year high for Construction in Progress was $863.4 million in Q2 2024, with the low at $70.8 million in Q1 2021.
  • Average Construction in Progress over 5 years is $394.4 million, with a median of $353.7 million recorded in 2025.
  • The sharpest move saw Construction in Progress surged 184.02% in 2023, then tumbled 80.56% in 2025.
  • Over 5 years, Construction in Progress stood at $186.8 million in 2021, then surged by 57.15% to $293.6 million in 2022, then soared by 152.23% to $740.6 million in 2023, then decreased by 11.69% to $654.0 million in 2024, then crashed by 80.56% to $127.2 million in 2025.
  • According to Business Quant data, Construction in Progress over the past three periods came in at $127.2 million, $129.1 million, and $353.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.